ABSTRACT
(LMPs), called latency IIb. This is followed by the long-term outgrowth of LCLs 23 expressing the EBNAs along with the LMPs, particularly the NFB-activating LMP1, 24 defining latency III. LCLs, however, express a broad distribution of LMP1 such that a 25 subset of these cells expresses LMP1 at levels seen in latency IIb, making it difficult to 26 distinguish these two latency states. In this study, we performed mRNA-Seq on early 27 EBV-infected latency IIb cells and latency III LCLs sorted by NFB activity. We found 28 that latency IIb transcriptomes clustered independently from latency III independent of 29 NFB. We identified and validated mRNAs defining these latency states. Indeed, we 30 were able to distinguish latency IIb cells from LCLs expressing low levels of LMP1 using 31 multiplex RNA-FISH targeting EBV EBNA2, LMP1, and human CCR7. This study 32 defines latency IIb as a bona fide latency state independent from latency III and 33 identifies biomarkers for understanding EBV-associated tumor heterogeneity. 1 mRNA abundance increased with increasing ICAM-1 MFI (Fig. 1B) . Importantly, 135 LMP1 mRNA abundance followed the same pattern as ICAM-1 (Fig. 1C) . In fact, there 136 was a direct linear correlation between ICAM-1 and LMP1 mRNA abundance, thereby 137 validating our sorting strategy (Fig. 1D) . genes ( Fig. 4C-D) . Latency III biomarkers were CCR7, MGST1, DST, and TSC22D3 192 and these displayed similar binary-like gene expression behavior ( Fig. 4E-F) . 201 5B), the difference in the percent of positive cells only dropped by half between day and 202 ICAM-1lo LCLs (Fig. 5C) . Similarly, while surface expression of CCR7 increased from 203 day 7 to LCL ( Fig. 5D-E Fig. 6A-B) . LMP1 expression was low in day 7 and higher, but 219 heterogeneous, in LCLs, as expected ( Fig. 6A-C) . CCR7 levels were low in EBNA2+ 220 day 7 cells and significantly higher in LCLs independent of LMP1 level ( Fig. 6D-E 
